頭孢洛扎
![]() | |
臨床資料 | |
---|---|
商品名 | Zerbaxa(與他唑巴坦聯用時) |
給藥途徑 | 靜脈注射 |
法律規範狀態 | |
法律規範 |
|
識別資訊 | |
| |
CAS號 | 689293-68-3 ![]() |
PubChem CID | |
CompTox Dashboard (EPA) | |
化學資訊 | |
化學式 | C23H30N12O8S2 |
摩爾質量 | 666.69 g·mol−1 |
3D模型(JSmol) | |
| |
|
頭孢洛扎[1](ceftolozane)是第五代頭孢類抗生素,用來治療對常規抗生素耐藥的革蘭氏陰性菌[2]。實驗證明其對尿路感染、腹腔內感染、呼吸機相關性細菌性肺炎有效。
頭孢洛扎常與他唑巴坦與β-內酰胺酶抑制劑他唑巴坦聯用,有防止頭孢洛扎分解的作用。聯用的頭孢洛扎/他唑巴坦商品名為「Zerbaxa」[3][4][5][6][7]。證據表明頭孢洛扎可以治療複雜尿路感染與複雜腹腔內感染[8]。
引用
- ^ 高田田; 沈承武. 新型抗菌药物头孢洛扎/他唑巴坦的研究进展. 解放軍藥學學報. 2017, 5.
- ^ Long, T. E.; Williams, J. T. Cephalosporins currently in early clinical trials for the treatment of bacterial infections. Expert Opinion on Investigational Drugs. 2014, 23 (10): 1375. doi:10.1517/13543784.2014.930127.
- ^ Takeda, S; Nakai, T; Wakai, Y; Ikeda, F; Hatano, K. In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy. 2007, 51 (3): 826–30. PMC 1803152
. PMID 17145788. doi:10.1128/AAC.00860-06.
- ^ Toda, A; Ohki, H; Yamanaka, T; Murano, K; Okuda, S; Kawabata, K; Hatano, K; Matsuda, K; Misumi, K; Itoh, K; Satoh, K; Inoue, S. Synthesis and SAR of novel parenteral anti-pseudomonal cephalosporins: Discovery of FR264205. Bioorganic & Medicinal Chemistry Letters. 2008, 18 (17): 4849–52. PMID 18701284. doi:10.1016/j.bmcl.2008.07.085.
- ^ Sader, H. S.; Rhomberg, P. R.; Farrell, D. J.; Jones, R. N. Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes. Antimicrobial Agents and Chemotherapy. 2011, 55 (5): 2390–4. PMC 3088243
. PMID 21321149. doi:10.1128/AAC.01737-10.
- ^ Craig, W. A.; Andes, D. R. In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum β-lactamases, in the thighs of neutropenic mice. Antimicrobial Agents and Chemotherapy. 2013, 57 (4): 1577–82. PMC 3623364
. PMID 23274659. doi:10.1128/AAC.01590-12.
- ^ Zhanel, G. G.; Chung, P; Adam, H; Zelenitsky, S; Denisuik, A; Schweizer, F; Lagacé-Wiens, P. R.; Rubinstein, E; Gin, A. S.; Walkty, A; Hoban, D. J.; Lynch Jp, 3rd; Karlowsky, J. A. Ceftolozane/tazobactam: A novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli. Drugs. 2014, 74 (1): 31–51. PMID 24352909. doi:10.1007/s40265-013-0168-2.
- ^ FDA approves new antibacterial drug Zerbaxa. 2014-12-09 [2015-06-02]. (原始內容存檔於2015-05-09).
|